ArticleESMO real world data and digital oncology2025
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.The oncologist · 2026Review
- Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.ESMO real world data and digital oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Palbociclib, ribociclib, and abemaciclib are approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC), in combination with aromatase inhibitors or fulvestrant. However, there is no standard care following progression on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Materials and methods: This study aimed to evaluate treatment patterns and effectiveness following the failure of CDK4/6i therapy. The analysis included 407 patients who received CDK4/6i in first- or second-line treatment across three cancer centers. Primary endpoints included time to next treatment (TTNT) and real-world progression-free survival. Results: The results demonstrated a median TTNT (mTTNT) of 26 months [95% confidence interval (CI) 21-31 months] for patients receiving CDK4/6i as first-line treatment. Subsequent therapies, including chemotherapy (CT), endocrine therapy (ET) with or without everolimus, and CDK4/6i-based regimens, were evaluated. The mTTNT for second-line treatments was 13 months (95% CI 9-16 months), with CT showing the longest duration [24 months (95% CI 17-30 months) versus 15 months (95% CI 11-18 months)] for CDK4/6-based regimens versus 9.6 months for everolimus with or without ET (95% CI 6-11 months). Multivariate analysis identified the number of disease sites as a significant predictor of longer TTNT in the first-line setting. Safety data revealed that CDK4/6i dose reductions due to toxicity occurred in 47% of patients, with neutropenia being the most common adverse event. Conclusions: These findings emphasize the variability in treatment efficacy following CDK4/6i therapy and underscore the importance of personalized treatment strategies. Further research is needed to optimize therapeutic sequences and improve patient outcomes in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.